Herbal extracts and phytochemicals: Plant secondary metabolites and the enhancement of human brain function

Advances in Nutrition

Volumn 2, Issue 1, 2011, Pages 32-50

  Kennedy, David O ^a   Wightman, Emma L ^a  

^a NORTHUMBRIA UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; FLAVONOID; PHENOL DERIVATIVE; PLANT EXTRACT;

ANIMAL; BRAIN; CHEMISTRY; DRUG EFFECT; GINKGO BILOBA; HUMAN; INSECT; MELISSA OFFICINALIS; METABOLISM; PANAX; PHYSIOLOGY; PHYTOTHERAPY; PLANT; PLANT PHYSIOLOGY; REVIEW; SALVIA OFFICINALIS;

ANIMALS; ANTIOXIDANTS; BRAIN; FLAVONOIDS; GINKGO BILOBA; HUMANS; INSECTS; MELISSA; PANAX; PHENOLS; PHYTOTHERAPY; PLANT EXTRACTS; PLANT PHYSIOLOGICAL PHENOMENA; PLANTS; SALVIA OFFICINALIS;

EID: 84856644400     PISSN: 21618313     EISSN: 21565376     Source Type: Journal    
DOI: 10.3945/an.110.000117     Document Type: Review

References (325)

1. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007;70:461-77.
2. Mukherjee PK, Kumar V, Mal M, Houghton PJ. Acetylcholinesterase inhibitors from plants. Phytomedicine. 2007;14:289-300.
3. National Institute of Clinical Excellence. NICE technology appraisal guidance. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (amended). London: National Institute of Clinical Excellence; 2009.
4. Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation. Grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med. 2008;23:854-9.
5. Pimentel D, Andow DA. Pest-management and pesticide impacts. Insect Sci Appl. 1984;5:141-9.
6. Reymond P, Weber H, Damond M, Farmer EE. Differential gene expression in response to mechanical wounding and insect feeding in Arabidopsis. Plant Cell. 2000;12:707-19.
7. Hermsmeier D, Schittko U, Baldwin IT. Molecular interactions between the specialist herbivore Manduca sexta (Lepidoptera, Sphingidae) and its natural host Nicotiana attenuata. I. Large-scale changes in the accumulation of growth-and defense-related plant mRNAs. Plant Physiol. 2001;125:683-700.
8. Harborne J. R. Introduction to ecological biochemistry. 4th ed. London: Elsevier; 1993.
9. Gershenzon J. The cost of plant chemical defense against herbivory: a biochemical perspective. In: Bernays EA, editor. Insect-plant interactions. Boca Raton (FL): CRC Press; 1994. p. 105-73.
10. Tahara S. A journey of twenty-five years through the ecological biochemistry of flavonoids. Biosci Biotechnol Biochem. 2007;71:1387-404.
11. Wink M. Evolution of secondary metabolites from an ecological and molecular phylogenetic perspective. Phytochemistry. 2003;64:3-19.
12. Rattan RS. Mechanism of action of insecticidal secondary metabolites of plant origin. Crop Prot. 2010;29:913-20.
13. Wink M. Interference of alkaloids with neuroreceptors and ion channels. Stud Nat Prod Chem. 2000;21:3-122.
14. Miller AE, Heyland A. Endocrine interactions between plants and animals: Implications of exogenous hormone sources for the evolution of hormone signaling. Gen Comp Endocrinol. 2010;166:455-61.
15. Schoonhoven L, Van Loon J, Dicke M. Insect-plant biology. Oxford: Oxford University Press; 2005.
16. Ødegaard F. How many species of arthropods? Erwin's estimate revised. Biol J Linn Soc Lond. 2000;71:583-97.
17. Bernays E, Graham M. On the evolution of host specificity in phytophagous arthropods. Ecology. 1988;69:886-92.
18. Ehrlich PR, Raven PH. Butterflies and plants: a study in coevolution. Evolution. 1964;18:586-608.
19. Kawashima K, Misawa H, Moriwaki Y, Fujii Y, Fujii T, Horiuchi Y, Yamada T, Imanaka T, Kamekura M. Ubiquitous expression of acetylcholine and its biological functions in life forms without nervous systems. Life Sci. 2007;80:2206-9.
20. Scott JG, Liu N,Wen Z. Insect cytochromes P450: diversity, insecticide resistance and tolerance to plant toxins. 1. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998;121:147-55.
21. Kushiro T, Nambara E, Mccourt P. Hormone evolution: the key to signalling. Nature. 2003;422:122.
22. Palavan-Unsal N, Arisan D. Nitric oxide signalling in plants. Bot Rev. 2009;75:203-29.
23. Dalle-Donne I, Rossi R, Colombo G, Giustarini D, Milzani A. Protein S-glutathionylation: a regulatory device from bacteria to humans. Trends Biochem Sci. 2009;34:85-96.
24. Scandalios JG. Oxidative stress: molecular perception and transduction of signals triggering antioxidant gene defenses. Braz J Med Biol Res. 2005;38:995-1014.
25. Lee D-S, Nioche P, Hamberg M, Raman CS. Structural insights into the evolutionary paths of oxylipin biosynthetic enzymes. Nature. 2008;455:363-8.
26. Thoma I, Krischke M, Loeffler C, Mueller MJ. The isoprostanoid pathway in plants. Chem Phys Lipids. 2004;128:135-48.
27. Iriti M, Faoro F. Review of innate and specific immunity in plants and animals. Mycopathologia. 2007;164:57-64.
28. Belhadj A, Saigne C, Telef N, Cluzet S, Bouscaut J, Corio-Costet MF, Merillon JM. Methyl jasmonate induces defense responses in grapevine and triggers protection against Erysiphe necator. J Agric Food Chem. 2006;54:9119-25.
29. Cohen S, Flescher E. Methyl jasmonate: a plant stress hormone as an anti-cancer drug. Phytochemistry. 2009;70:1600-9.
30. Nässel DR, Winther AM. Drosophila neuropeptides in regulation of physiology and behavior. Prog Neurobiol. 2010;92:42-104.
31. Klowden MJ. Physiological systems in insects. London: Academic Press; 2007.
32. Marder E. Searching for insight. In: North G, Greenspan RJ, editors. Invertebrate neurobiology. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2007.
33. Wolf FW, Heberlein U. Invertebrate models of drug abuse. J Neurobiol. 2003;54:161-78.
34. Farooqui T. Octopamine-mediated neuromodulation of insect senses. Neurochem Res. 2007;32:1511-29.
35. Daniels RW, Gelfand MV, Collins CA, Diantonio A. Visualizing glutamatergic cell bodies and synapses in Drosophila larval and adult CNS. J Comp Neurol. 2008;508:131-52.
36. Ismail N, Christine S, Robinson GE, Fahrbach SE. Pilocarpine improves recognition of nestmates in young honey bees. Neurosci Lett. 2008;439:178-81.
37. Dacher M, Gauthier M. Involvement of NO-synthase and nicotinic receptors in learning in the honey bee. Physiol Behav. 2008;95: 200-7.
38. Nakatani Y, Matsumoto Y, Mori Y, Hirashima D, Nishino H, Arikawa K, Mizunami M. Why the carrot is more effective than the stick: different dynamics of punishment memory and reward memory and its possible biological basis. Neurobiol Learn Mem. 2009;92:370-80.
39. Menzel R, Manz G. Neural plasticity of mushroom body-extrinsic neurons in the honeybee brain. J Exp Biol. 2005;208:4317-32.
40. Matsumoto Y, Hatano A, Unoki S, Mizunami M. Stimulation of the cAMP system by the nitric oxide-cGMP system underlying the formation of long-term memory in an insect. Neurosci Lett. 2009;467: 81-5.
41. Glanzman DL. Simple minds: the neurobiology of invertebrate learning and memory. In: North G, Greenspan RJ, editors. Invertebrate neurobiology. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2007.
42. Giurfa M. Invertebrate cognition: nonelemental learning beyond simple conditioning. In: North G, Greenspan RJ, editors. Invertebrate neurobiology. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2007.
43. Menzel R. Electrophysiology and optophysiology of complex brain functions in insects. In: North G, Greenspan RJ, editors. Invertebrate neurobiology. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2007.
44. Mixson TA, Abramson CI, Bozi J. The behavior and social communication of honey bees (Apis mellifera carnica) poll.) Under the influence of alcohol 1, 2. Psychol Rep. 2010;106:701-17.
45. Catterson JH, Knowles-Barley S, James K, Heck MM, Harmar AJ, Hartley PS. Dietary modulation of Drosophila sleep-wake behaviour. PLoS ONE. 2010;5:e12062.
46. Ho KS, Sehgal A. Drosophila melanogaster: an insect model for fundamental studies of sleep. Methods Enzymol. 2005;393:772-93.
47. Horiuchi J, Saitoe M. Can flies shed light on our own age-related memory impairment? Ageing Res Rev. 2005;4:83-101.
48. Thamm M, Balfanz S, Scheiner R, Baumann A, Blenau W. Characterization of the 5-HT 1A receptor of the honeybee (Apis mellifera) and involvement of serotonin in phototactic behavior. Cell Mol Life Sci. 2010;67:2467-79.
49. Mustard JA, Pham PM, Smith BH. Modulation of motor behavior by dopamine and the D1-like dopamine receptor AmDOP2 in the honey bee. J Insect Physiol. 2010;56:422-30.
50. El Hassani AK, Dupuis JP, Gauthier M, Armengaud C. Glutamatergic and GABAergic effects of fipronil on olfactory learning and memory in the honeybee. Invert Neurosci. 2009;9:91-100.
51. El Hassani AK, Giurfa M, Gauthier M, Armengaud C. Inhibitory neurotransmission and olfactory memory in honeybees. Neurobiol Learn Mem. 2008;90:589-95.
52. Guez D, Zhu H, Zhang S, Srinivasan M. Enhanced cholinergic transmission promotes recall in honeybees. J Insect Physiol. 2010;56:1341-8.
53. Schultz JC. Shared signals and the potential for phylogenetic espionage between plants and animals. Integr Comp Biol. 2002;42:454-62.
54. Zhang ZJ. Therapeutic effects of herbal extracts and constituents in animal models of psychiatric disorders. Life Sci. 2004;75:1659-99.
55. Zulak K, Liscombe D, Ashihara H, Facchini P. Alkaloids. Plant secondary metabolism in diet and human health. Oxford: Blackwell Publishing; 2006. p. 102-36.
56. Goldman P. Herbal medicines today and the roots of modern pharmacology. Ann Intern Med. 2001;135:594-600.
57. Zenk MH, Juenger M. Evolution and current status of the phytochemistry of nitrogenous compounds. Phytochemistry. 2007;68:2757-72.
58. Hagen EH, Sullivan RJ, Schmidt R, Morris G, Kempter R, Hammerstein P. Ecology and neurobiology of toxin avoidance and the paradox of drug reward. Neuroscience. 2009;160:69-84.
59. Ashihara H, Sano H, Crozier A. Caffeine and related purine alkaloids: biosynthesis, catabolism, function and genetic engineering. Phytochemistry. 2008;69:841-56.
60. Baumann T, Gabriel H. Metabolism and excretion of caffeine during germination of Coffea arabica L. Plant Cell Physiol. 1984;25:1431.
61. Shaw PJ, Cirelli C, Greenspan RJ, Tononi G. Correlates of sleep and waking in Drosophila melanogaster. Science. 2000;287:1834.
62. Nishi Y, Sasaki K, Miyatake T. Biogenic amines, caffeine and tonic immobility in Tribolium castaneum. J Insect Physiol. 2010;56:622-8.
63. Andretic R, Kim YC, Jones FS, Han KA, Greenspan RJ. Drosophila D1 dopamine receptor mediates caffeine-induced arousal. Proc Natl Acad Sci USA. 2008;105:20392-7.
64. Ferré S. An update on the mechanisms of the psychostimulant effects of caffeine. J Neurochem. 2008;105:1067-79.
65. Laurienti PJ, Field AS, Burdette JH, Maldjian JA, Yen YF, Moody DM. Relationship between caffeine-induced changes in resting cerebral perfusion and blood oxygenation level-dependent signal. AJNR Am J Neuroradiol. 2003;24:1607.
66. Addicott MA, Laurienti PJ. A comparison of the effects of caffeine following abstinence and normal caffeine use. Psychopharmacology (Berl). 2009;207:423-31.
67. Sigmon SC, Herning RI, Better W, Cadet JL, Griffiths RR. Caffeine withdrawal, acute effects, tolerance, and absence of net beneficial effects of chronic administration: cerebral blood flow velocity, quantitative EEG, and subjective effects. Psychopharmacology (Berl). 2009; 204:573-85.
68. James JE, Rogers PJ. Effects of caffeine on performance and mood: withdrawal reversal is the most plausible explanation. Psychopharmacology (Berl). 2005;182:1-8.
69. Haskell CF, Kennedy DO, Wesnes KA, Scholey AB. Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. Psychopharmacology (Berl). 2005;179: 813-25.
70. Hewlett P, Smith A. Acute effects of caffeine in volunteers with different patterns of regular consumption. Hum Psychopharmacol. 2006; 21:167-80.
71. Reissig CJ, Strain EC, Griffiths RR. Caffeinated energy drinks: a growing problem. Drug Alcohol Depend. 2009;99:1-10.
72. Haskell CF, Kennedy DO, Wesnes KA, Milne AL, Scholey AB. A double-blind, placebo-controlled, multi-dose evaluation of the acute behavioural effects of guaraná in humans. J Psychopharmacol. 2007; 21:65.
73. Rogers PJ, Smith JE, Heatherley SV, Pleydell-Pearce CW. Time for tea: mood, blood pressure and cognitive performance effects of caffeine and theanine administered alone and together. Psychopharmacology (Berl). 2008;195:569-77.
74. Haskell CF, Kennedy DO, Milne AL, Wesnes KA, Scholey AB. The effects of L-theanine, caffeine and their combination on cognition and mood. Biol Psychol. 2008;77:113-22.
75. Di Matteo V, Pierucci M, Di Giovanni G, Benigno A, Esposito E. The neurobiological bases for the pharmacotherapy of nicotine addiction. Curr Pharm Des. 2007;13:1269-84.
76. Poorthuis RB, Goriounova NA, Couey JJ, Mansvelder HD. Nicotinic actions on neuronal networks for cognition: general principles and long-term consequences. Biochem Pharmacol. 2009;78:668-76.
77. Mansvelder HD, van Aerde KI, Couey JJ, Brussaard AB. Nicotinic modulation of neuronal networks: from receptors to cognition. Psychopharmacology (Berl). 2006;184:292-305.
78. Heishman SJ, Kleykamp BA, Singleton EG. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology (Berl). 2010;210:453-69.
79. Levin ED, Conners CK, Silva D, Hinton SC, Meck WH, March J, Rose JE. Transdermal nicotine effects on attention. Psychopharmacology (Berl). 1998;140:135-41.
80. Lozano VC, Armengaud C, Gauthier M. Memory impairment induced by cholinergic antagonists injected into the mushroom bodies of the honeybee. J Comp Physiol A. 2001;187:249-254.
81. Cano Lozano V, Gauthier M. Effects of the muscarinic antagonists atropine and pirenzepine on olfactory conditioning in the honeybee. Pharmacol Biochem Behav. 1998;59:903-7.
82. Carnicella S, Pain L, Oberling P. Cholinergic effects on fear conditioning II: nicotinic and muscarinic modulations of atropine-induced disruption of the degraded contingency effect. Psychopharmacology (Berl). 2005;178:533-41.
83. Bartus RT, Dean RL. Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps. Psychopharmacology (Berl). 2009;202:15-36.
84. Kucharski R, Maleszka R. Microarray and real-time PCR analyses of gene expression in the honeybee brain following caffeine treatment. J Mol Neurosci. 2005;27:269-76.
85. Heberlein U, Tsai LTY, Kapfhamer D, Lasek AW. Drosophila, a genetic model system to study cocaine-related behaviors: a review with focus on LIM-only proteins. Neuropharmacology. 2009;56:97-106.
86. Mcclung C, Hirsh J. Stereotypic behavioral responses to free-base cocaine and the development of behavioral sensitization in Drosophila. Curr Biol. 1998;8:109-12.
87. Barron AB, Maleszka R, Helliwell PG, Robinson GE. Effects of cocaine on honey bee dance behaviour. J Exp Biol. 2009;212:163-8.
88. Pérez-Mañá C, Castells X, Vidal X, Casas M, Capellà D. Efficacy of indirect dopamine agonists for psychostimulant dependence: A systematic review and meta-analysis of randomized controlled trials. J Subst Abuse Treat. In press 2010.
89. WHO. Neuroscience of psychoactive use and dependence. Geneva: WHO; 2004.
90. Andretic R, van Swinderen B, Greenspan RJ. Dopaminergic modulation of arousal in Drosophila. Curr Biol. 2005;15:1165-75.
91. Caveney S, Charlet DA, Freitag H, Maier-Stolte M, Starratt AN. New observations on the secondary chemistry of World Ephedra (Ephedraceae). Am J Bot. 2001;88:1199-208.
92. Gritsai OB, Dubynin VA, Pilipenko VE, Petrov OP. Effects of peptide and non-peptide opioids on protective reaction of the cockroach Periplaneta americana in the "hot camera". J Evol Biochem Physiol. 2004; 40:153-60.
93. Dyakonova VE. Role of opioid peptides in behavior of invertebrates. J Evol Biochem Physiol. 2001;37:335-47.
94. WHO. Neuroscience of psychoactive use and dependence. Geneva: WHO; 2004.
95. Tan J, Galligan JJ, Hollingworth RM. Agonist actions of neonicotinoids on nicotinic acetylcholine receptors expressed by cockroach neurons. Neurotoxicology. 2007;28:829-42.
96. Bainton RJ, Tsai LT, Singh CM, Moore MS, Neckameyer WS, Heberlein U. Dopamine modulates acute responses to cocaine, nicotine and ethanol in Drosophila. Curr Biol. 2000;10:187-94.
97. van den Beukel I, van Kleef R, Oortgiesen M. Differential effects of physostigmine and organophosphates on nicotinic receptors in neuronal cells of different species. Neurotoxicology. 1998;19:777-87.
98. Militante J, Ma BW, Akk G, Steinbach JH. Activation and block of the adult muscle-type nicotinic receptor by physostigmine: single-channel studies. Mol Pharmacol. 2008;74:764-76.
99. Prediger RDS, De-Mello N, Takahashi RN. Pilocarpine improves olfactory discrimination and social recognition memory deficits in 24 month-old rats. Eur J Pharmacol. 2006;531:176-82.
100. Rupniak NMJ, Steventon MJ, Field MJ, Jennings CA, Iversen SD. Comparison of the effects of 4 cholinomimetic agents on cognition in primates following disruption by scopolamine or by lists of objects. Psychopharmacology (Berl). 1989;99:189-95.
101. Ebert U, Kirch W. Review: scopolamine model of dementia: electroencephalogram findings and cognitive performance. Eur J Clin Invest. 1998;28:944-9.
102. Rohmer M. The discovery of a mevalonate-independent pathway for isoprenoid biosynthesis in bacteria, algae and higher plants. Nat Prod Rep. 1999;16:565-74.
103. de Almeida LFR, Frei F, Mancini E, De Martino L, De Feo V. Phytotoxic activities of Mediterranean essential oils. Molecules. 2010;15: 4309-23.
104. De Martino L, Mancini E, de Almeida LFR, De Feo V. The antigerminative activity of twenty-seven monoterpenes. Molecules. 2010;15: 6630-7.
105. Céspedes CL, Salazar JR, Martínez M, Aranda E. Insect growth regulatory effects of some extracts and sterols from Myrtillocactus geometrizans (Cactaceae) against Spodoptera frugiperda and Tenebrio molitor. Phytochemistry. 2005;66:2481-93.
106. Kennedy D, Dodd F, Robertson B, Okello E, Reay J, Scholey A, Haskell C. Monoterpenoid extract of sage (Salvia lavandulaefolia) with cholinesterase inhibiting properties improves cognitive performance and mood in healthy adults. J Psychopharmacol. Epub 2010 Oct 11.
107. Barney JN, Hay AG, Weston LA. Isolation and characterization of allelopathic volatiles from mugwort (Artemisia vulgaris). J Chem Ecol. 2005;31:247-65.
108. Jiang Z, Akhtar Y, Bradbury R, Zhang X, Isman MB. Comparative toxicity of essential oils of Litsea pungens and Litsea cubeba and blends of their major constituents against the cabbage looper, Trichoplusia ni. J Agric Food Chem. 2009;57:4833-7.
109. Nerio LS, Olivero-Verbel J, Stashenko E. Repellent activity of essential oils: a review. Bioresour Technol. 2010;101:372-8.
110. González-Coloma A, Martín-Benito D, Mohamed N, García-Vallejo MC, Soria AC. Antifeedant effects and chemical composition of essential oils from different populations of Lavandula luisieri L. Biochem Syst Ecol. 2006;34:609-16.
111. Savelev S, Okello E, Perry NSL, Wilkins RM, Perry EK. Synergistic and antagonistic interactions of anticholinesterase terpenoids in Salvia lavandulaefolia essential oil. Pharmacol Biochem Behav. 2003;75: 661-8.
112. Savelev SU, Okello EJ, Perry EK. Butyryl-and acetyl-cholinesterase inhibitory activities in essential oils of Salvia species and their constituents. Phytother Res. 2004;18:315-24.
113. Berger P. Ginkgo leaf extract. Medical Herbalism. 2001;2:5-6.
114. Kleijnen J, Knipschild P. Ginkgo-biloba. Lancet. 1992;340:1136-9.
115. Ahn Y, Kwon M, Park H, Han C. Potent insecticidal activity of Ginkgo biloba derived trilactone terpenes against Nilaparvata lugens. Phytochemicals for Pest Control. 1997;658:90-105.
116. Matsumoto T, Sei T. Antifeedant activities of Ginkgo biloba L. components against the larva of Pieris rapae crucivora. Agric Biol Chem. 1987;51:249-50.
117. Mazzanti G, Mascellino M, Battinelli L, Coluccia D, Manganaro M, Saso L. Antimicrobial investigation of semipurified fractions of Ginkgo biloba leaves. J Ethnopharmacol. 2000;71:83-8.
118. He X, Huang W, Chen W, Dong T, Liu C, Chen Z, Xu S, Ruan Y. Changes of main secondary metabolites in leaves of Ginkgo biloba in response to ozone fumigation. J Environ Sci (China). 2009;21: 199-203.
119. Huang W, He X, Chen W, Chen Z, Ruan Y, Xu S. Influence of elevated carbon dioxide and ozone on the foliar nonvolatile terpenoids in ginkgo biloba. Bull Environ Contam Toxicol. 2008;81:432-5.
120. Defeudis FV, Drieu K. "Stress-alleviating" and "vigilance-enhancing" actions of Ginkgo biloba extract (EGb 761). Drug Dev Res. 2004;62: 1-25.
121. Chan PC, Xia QS, Fu PP. Ginkgo biloba leave extract: biological, medicinal, and toxicological effects. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2007;25:211-44.
122. Fehske CJ, Leuner K, Müller WE. Ginkgo biloba extract (EGb761®) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment. Pharmacol Res. 2009;60:68-73.
123. Hindmarch I. Activity of ginkgo biloba extract on short-term-memory. Presse Med. 1986;15:1592-4.
124. Rigney U, Kimber S, Hindmarch I. The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers. Phytother Res. 1999;13:408-15.
125. Warot D, Lacomblez L, Danjou P, Weiller E, Payan C, Puech AJ. Comparative effects of Ginkgo biloba extracts on psychomotor performances and memory in healthy-volunteers. Therapie. 1991;46: 33-6.
126. Kennedy DO, Scholey AB, Wesnes KA. The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacology (Berl). 2000;151:416-23.
127. Kennedy DO, Jackson PA, Haskell CF, Scholey AB. Modulation of cognitive performance following single doses of 120 mg Ginkgo biloba extract administered to healthy young volunteers. Hum Psychopharmacol. 2007;22:559-66.
128. Stough C, Clarke J, Lloyd J, Nathan PJ. Neuropsychological changes after 30-day Ginkgo biloba administration in healthy participants. Int J Neuropsychopharmacol. 2001;4:131-4.
129. Mix JA, Crews WD. An examination of the efficacy of Ginkgo biloba extract EGb 761 on the neuropsychologic functioning of cognitively intact older adults. J Altern Complement Med. 2000;6:219-29.
130. Mix JA, Crews WD. A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 (R) in a sample of cognitively intact older adults: neuropsychological findings. Hum Psychopharmacol. 2002;17:267-77.
131. Solomon PR, Adams F, Silver A, Zimmer J, Deveaux R. Ginkgo for memory enhancement: a randomized controlled trial. JAMA. 2002; 288:835-40.
132. Moulton PL, Boyko LN, Fitzpatrick JL, Petros TV. The effect of Ginkgo biloba on memory in healthy male volunteers. Physiol Behav. 2001;73:659-65.
133. Birks JG, Grimley E, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2009;CD003120.
134. Birks J, Evans JG. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2009:CD003120.
135. Kaschel R. Ginkgo biloba: specificity of neuropsychological improvementa selective review in search of differential effects. Human Psychopharmacol. 2009;24:345-70.
136. Kennedy DO, Scholey AB. The psychopharmacology of European herbs with cognition-enhancing properties. Curr Pharm Des. 2006; 12:4613-23.
137. Tittel G, Wagner H, Bos R. Chemical-composition of the essential oil from melissa. Planta Med. 1982;46:91-8.
138. Ntalli NG, Ferrari F, Giannakou I, Menkissoglu-Spiroudi U. Phytochemistry and nematicidal activity of the essential oils from 8 greek lamiaceae aromatic plants and 13 terpene components. J Agric Food Chem. 2010;58:7856-63.
139. Koliopoulos G, Pitarokili D, Kioulos E, Michaelakis A, Tzakou O. Chemical composition and larvicidal evaluation of Mentha, Salvia, and Melissa essential oils against the West Nile virus mosquito Culex pipiens. Parasitol Res. 2010;107:327-35.
140. Pereira RP, Fachinetto R, de Souza Prestes A, Puntel R, Santos da Silva G, Heinzmann B, Boschetti T, Athayde M, Bürger M, et al. Antioxidant effects of different extracts from Melissa officinalis, Matricaria recutita and Cymbopogon citratus. Neurochem Res. 2009;34:973-83.
141. Ferreira A, Proença C, Serralheiro MLM, Araújo MEM. The in vitro screening for acetylcholinesterase inhibition and antioxidant activity of medicinal plants from Portugal. Journal of Ethnopharmacology. 2006;108:31-7.
142. Perry N, Court G, Bidet N, Court J, Perry E. European herbs with cholinergic activities: potential in dementia therapy. Int J Geriatr Psychiatry. 1996;11:1063-9.
143. Wake G, Court J, Pickering A, Lewis R, Wilkins R, Perry E. CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory. J Ethnopharmacol. 2000;69: 105-14.
144. Dastmalchi K, Ollilainen V, Lackman P, Gennäs GBA, Dorman HJD, Järvinen PP, Yli-Kauhaluoma J, Hiltunen R. Acetylcholinesterase inhibitory guided fractionation of Melissa officinalis L. Bioorg Med Chem. 2009;17:867-71.
145. Salah SM, Jäger AK. Screening of traditionally used Lebanese herbs for neurological activities. J Ethnopharmacol. 2005;97:145-9.
146. Awad R, Muhammad A, Durst T, Trudeau VL, Arnason JT. Bioassayguided fractionation of lemon balm (Melissa officinalis L.) using an in vitro measure of GABA transaminase activity. Phytother Res. 2009;23: 1075-81.
147. Abuhamdah S, Huang L, Elliott M, Howes M, Ballard C, Holmes C, Burns A, Perry E, Francis P, et al. Pharmacological profile of an essential oil derived from Melissa officinalis with anti agitation properties: focus on ligand gated channels. J Pharm Pharmacol. 2008;60:377-84.
148. Ibarra A, Feuillere N, Roller M, Lesburgere E, Beracochea D. Effects of chronic administration of Melissa officinalis L. extract on anxiety-like reactivity and on circadian and exploratory activities in mice. Phytomedicine. 2010;17:397-403.
149. Gertsch J, Leonti M, Raduner S, Racz I, Chen JZ, Xie XQ, Altmann KH, Karsak M, Zimmer A. Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci USA. 2008;105:9099-104.
150. Kennedy DO, Scholey AB, Tildesley NTJ, Perry EK, Wesnes KA. Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacol Biochem Behav. 2002;72:953-64.
151. Kennedy DO, LittleW, Scholey AB. Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (Lemon Balm). Psychosom Med. 2004;66:607.
152. Kennedy DO, Wake G, Savelev S, Tildesley NTJ, Perry EK, Wesnes KA, Scholey AB. Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. Neuropsychopharmacology. 2003;28:1871-81.
153. Ballard CG, O'Brien JT, Reichelt K, Perry EK. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiatry. 2002;63:553-8.
154. Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial. J Neurol Neurosurg Psychiatry. 2003;74:863-6.
155. Yun T. Brief introduction of Panax ginseng CA Meyer. J Korean Med Sci. 2001;16:3-5.
156. Lu JM, Yao QZ, Chen CY. Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol. 2009;7:293-302.
157. Osbourn A. Saponins and plant defence: a soap story. Trends Plant Sci. 1996;1:4-9.
158. Sparg SG, Light ME, van Staden J. Biological activities and distribution of plant saponins. J Ethnopharmacol. 2004;94:219-43.
159. Kennedy DO, Scholey AB. Ginseng: potential for the enhancement of cognitive performance and mood. Pharmacol Biochem Behav. 2003; 75:687-700.
160. Dang H, Chen Y, Liu X, Wang Q, Wang L, Jia W, Wang YQ. Antidepressant effects of ginseng total saponins in the forced swimming test and chronic mild stress models of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1417-24.
161. Kennedy DO, Scholey AB, Wesnes KA. Differential, dose dependent changes in cognitive performance following acute administration of a Ginkgo biloba/Panax ginseng combination to healthy young volunteers. Nutr Neurosci. 2001;4:399-412.
162. Kennedy DO, Scholey AB, Wesnes KA. Modulation of cognition and mood following administration of single doses of Ginkgo biloba, ginseng, and a ginkgo/ginseng combination to healthy young adults. Physiol Behav. 2002;75:739-51.
163. Kennedy DO, Haskell CF,Wesnes KA, Scholey AB. Improved cognitive performance in human volunteers following administration of guarana (Paullinia cupana) extract: comparison and interaction with Panax ginseng. Pharmacol Biochem Behav. 2004;79:401-11.
164. Kennedy DO, Scholey AB, Drewery L, Marsh VR, Moore B, Ashton H. Electroencephalograph effects of single doses of Ginkgo biloba and Panax ginseng in healthy young volunteers. Pharmacol Biochem Behav. 2003;75:701-9.
165. Reay JL, Kennedy DO, Scholey AB. Single doses of Panax ginseng (G115) reduce blood glucose levels and improve cognitive performance during sustained mental activity. J Psychopharmacol. 2005; 19:357-65.
166. Reay JL, Kennedy DO, Scholey AB. Effects of Panax ginseng, consumed with and without glucose, on blood glucose levels and cognitive performance during sustained'mentally demanding'tasks. J Psychopharmacol. 2006;20:771.
167. Reay JL, Scholey AB, Kennedy DO. Panax ginseng (G115) improves aspects of working memory performance and subjective ratings of calmness in healthy young adults. Hum Psychopharmacol. 2010;25: 462-71.
168. Olsen RW. Absinthe and gamma-aminobutyric acid receptors. Proc Natl Acad Sci USA. 2000;97:4417-8.
169. Perry NSL, Houghton PJ, Theobald A, Jenner P, Perry EK. In-vitro inhibition of human erythrocyte acetylcholinesterase by Salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol. 2000;52:895-902.
170. Perry NSL, Bollen C, Perry EK, Ballard C. Salvia for dementia therapy: review of pharmacological activity and pilot tolerability clinical trial. Pharmacology Biochemistry and Behavior. 2003;75:651-9.
171. Perry NSL, Houghton PJ, Jenner P, Keith A, Perry EK. Salvia lavandulaefolia essential oil inhibits cholinesterase in vivo. Phytomedicine. 2002;9:48-51.
172. Orhan I, Kartal M, Kan Y, Sener B. Activity of essential oils and individual components against acetyl and butyrylcholinesterase. Z Naturforsch C. 2008;63:547-53.
173. Perry NSL, Houghton PJ, Sampson J, Theobald AE, Hart S, Lis-Balchin M, Hoult JRS, Evans P, Jenner P, et al. In-vitro activity of S-lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer's disease. J Pharm Pharmacol. 2001;53:1347-56.
174. Tildesley NTJ, Kennedy DO, Perry EK, Ballard CG, Savelev S, Wesnes KA, Scholey AB. Salvia lavandulaefolia (Spanish Sage) enhances memory in healthy young volunteers. Pharmacol Biochem Behav. 2003;75: 669-74.
175. Tildesley NTJ, Kennedy DO, Perry EK, Ballard CG, Wesnes KA, Scholey AB. Positive modulation of mood and cognitive performance following administration of acute doses of Salvia lavandulaefolia essential oil to healthy young volunteers. Physiol Behav. 2005;83:699-709.
176. Scholey AB, Tildesley NT, Ballard CG,Wesnes KA, Tasker A, Perry EK, Kennedy DO. An extract of Salvia (sage) with anticholinesterase properties improves memory and attention in healthy older volunteers. Psychopharmacology (Berl). 2008;198:127-39.
177. Kennedy DO, Pace S, Haskell C, Okello EJ, Milne A, Scholey AB. Effects of cholinesterase inhibiting sage (Salvia officinalis) on mood, anxiety and performance on a psychological stressor. Neuropsychopharmacology. 2006;31:845-52.
178. Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. J Clin Pharm Ther. 2003;28:53-9.
179. Houghton PJ. The biological activity of valerian and related plants. J Ethnopharmacol. 1988;22:121-42.
180. Houghton PJ. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol. 1999;51:505-12.
181. Kittipongpatana N, Davis DL, Porter JR. Methyl jasmonate increases the production of valepotriates by transformed root cultures of Valerianella locusta. Plant Cell Tissue Organ Cult. 2002;71:65-75.
182. Marder M, Viola H, Wasowski C, Fernández S, Medina J, Paladini A. 6-Methylapigenin and hesperidin: new valeriana flavonoids with activity on the CNS. Pharmacol Biochem Behav. 2003;75:537-45.
183. Dietz BM, Mahady GB, Pauli GF, Farnsworth NR. Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro. Brain Res Mol Brain Res. 2005;138:191-7.
184. Khom S, Baburin I, Timin E, Hohaus A, Trauner G, Kopp B, Hering S. Valerenic acid potentiates and inhibits GABAA receptors: molecular mechanism and subunit specificity. Neuropharmacology. 2007;53:178-87.
185. Lacher SK, Mayer R, Sichardt K, Nieber K, Müller CE. Interaction of valerian extracts of different polarity with adenosine receptors: identification of isovaltrate as an inverse agonist at A1 receptors. Biochem Pharmacol. 2007;73:248-58.
186. Murphy K, Kubin ZJ, Shepherd JN, Ettinger RH. Valeriana officinalis root extracts have potent anxiolytic effects in laboratory rats. Phytomedicine. 2010;17:674-8.
187. Benke D, Barberis A, Kopp S, Altmann KH, Schubiger M, Vogt KE, Rudolph U, Mohler H. GABA(A) receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropharmacology. 2009;56:174-81.
188. Gerhard U, Linnenbrink N, Georghiadou C, Hobi V. Vigilanzmindernde Effekte zweier pflanzlicher Schlafmittel [Vigilance-decreasing effects of 2 plant-derived sedatives]. Revue Suisse Medecine Praxis 1996;85.
189. Kuhlmann J, Berger W, Podzuweit H, Schmidt U. The influence of valerian treatment on 'reaction time, alertness and concentration' in volunteers. Pharmacopsychiatry. 1999;32:235-41.
190. Ziegler G, Ploch M, Miettinen-Baumann A, Collet W. Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia: a randomized, double-blind, comparative clinical study. Eur J Med Res. 2002;7:480-6.
191. Schmitz M, Jackel M. Comparative study for assessing quality of life of patients with exogenous sleep disorders (temporary sleep onset and sleep interruption disorders) treated with a hops-valerian preparation and a benzodiazepine drug. Wien Med Wochenschr. 1998;148:291-8.
192. Fussel A, Wolf A, Brattstrom A. Effect of a fixed valerian-Hop extract combination (Ze 91019) on sleep polygraphy in patients with nonorganic insomnia: a pilot study. Eur J Med Res. 2000;5:385-90.
193. Miyasaka L, Atallah A, Soares B. Valerian for anxiety disorders. Cochrane Database Syst Rev. 2006:CD004515.
194. Stevinson C, Ernst E. Valerian for insomnia: a systematic review of randomized clinical trials. Sleep Med. 2000;1:91-9.
195. Bent S, Padula A, Moore D, Patterson M, Mehling W. Valerian for sleep: a systematic review and meta-analysis. Am J Med. 2006;119: 1005-12.
196. Fernández-San-Martín MI, Masa-Font R, Palacios-Soler L, Sancho-Gómez P, Calbó-Caldentey C, Flores-Mateo G. Effectiveness of valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med. 2010;11:505-11.
197. Bowsher CS, Tobin M. Plant Biochemistry A. New York: Garland Science; 2008.
198. Diaz Napal GN, Defago MT, Valladares GR, Palacios SM. Response of Epilachna paenulata to two flavonoids, pinocembrin and quercetin, in a comparative study. J Chem Ecol. 2010;36:898-904.
199. Treutter D. Significance of flavonoids in plant resistance: a review. Environ Chem Lett. 2006;4:147-57.
200. Ren L, Wang F, Xu Z, Chan WM, Zhao C, Xue H. GABAA receptor subtype selectivity underlying anxiolytic effect of 6-hydroxyflavone. Biochem Pharmacol. 2010;79:1337-44.
201. Dhawan K, Dhawan S, Sharma A. Passiflora: a review update. J Ethnopharmacol. 2004;94:1-23.
202. Kim DH, Jeon SJ, Son KH, Jung JW, Lee S, Yoon BH, Lee J-J, Cho Y-W, Cheong JH, et al. The ameliorating effect of oroxylin A on scopolamine-induced memory impairment in mice. Neurobiol Learn Mem. 2007;87:536-46.
203. Xu Y, Wang Z, You W, Zhang X, Li S, Barish P, Vernon M, Du X, Li G, et al. Antidepressant-like effect of trans-resveratrol: involvement of serotonin and noradrenaline system. Eur Neuropsychopharmacol. 2010; 20:405-13.
204. Dixon RA. Phytoestrogens. Annu Rev Plant Biol. 2004;55:225-61.
205. Rochester JR Millam JR. Phytoestrogens and avian reproduction: exploring the evolution and function of phytoestrogens and possible role of plant compounds in the breeding ecology of wild birds. Comp Biochem Physiol A Mol Integr Physiol. 2009;154:279-88.
206. Steffen LM. Eat your fruit and vegetables. Lancet. 2006;367:278-9.
207. Vingtdeux V, Dreses-Werringloer U, Zhao H, Davies P, Marambaud P. Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neurosci. 2008;9:S6.
208. Commenges D, Scotet V, Renaud S, Jacqmin-Gadda H, Barberger-Gateau P, Dartigues JF. Intake of flavonoids and risk of dementia. Eur J Epidemiol. 2000;16:357-63.
209. Ng TP, Feng L, Niti M, Kua EH, Yap KB. Tea consumption and cognitive impairment and decline in older Chinese adults. Am J Clin Nutr. 2008;88:224-31.
210. Nurk E, Refsum H, Drevon CA, Tell GS, Nygaard HA, Engedal K, Smith AD. Intake of flavonoid-rich wine, tea, and chocolate by elderly men and women is associated with better cognitive test performance. J Nutr. 2009;139:120-7.
211. Willis LM, Shukitt-Hale B, Joseph JA. Recent advances in berry supplementation and age-related cognitive decline. Curr Opin Clin Nutr Metab Care. 2009;12:91.
212. Francis ST, Head K, Morris PG, Macdonald IA. The effect of flavanolrich cocoa on the fMRI response to a cognitive task in healthy young people. J Cardiovasc Pharmacol. 2006;47:215-20.
213. Scholey A, French S, Morris P, Kennedy D, Milne A, Haskell C. Consumption of cocoa flavanols results in acute improvements in mood and cognitive performance during sustained mental effort. J Psychopharmacol 2009.
214. Spencer J. The impact of fruit flavonoids on memory and cognition. Br J Nutr. 2010;104:40-7.
215. Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med. 1991;57:1-7.
216. Araujo C, Leon L. Biological activities of Curcuma longa L. Mem Inst Oswaldo Cruz. 2001;96:723-8.
217. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci. 2009;30:85-94.
218. Yang C, Zhang X, Fan H, Liu Y. Curcumin upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia. Brain Res. 2009;1282:133-41.
219. Jagetia GC, Aggarwal BB. "Spicing up" of the immune system by curcumin. J Clin Immunol. 2007;27:19-35.
220. Narlawar R, Pickhardt M, Leuchtenberger S, Baumann K, Krause S, Dyrks T, Weggen S, Mandelkow E, Schmidt B. Curcumin-derived pyrazoles and isoxazoles: Swiss Army knives or blunt tools for Alzheimer's Disease? ChemMedChem. 2008;3:3-5.
221. Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent antiamyloidogenic effects for Alzheimer's: amyloid fibrils in vitro. J Neurosci Res. 2004;75:742-50.
222. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001;21:8370.
223. Natarajan C, Bright J. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J Immunol. 2002;168:6506.
224. Zbarsky V, Datla K, Parkar S, Rai D, Aruoma O, Dexter D. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radic Res. 2005;39:1119-25.
225. Calabrese V, Scapagnini G, Colombrita C, Ravagna A, Pennisi G, Giuffrida Stella A, Galli F, Butterfield D. Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Amino Acids. 2003;25:437-44.
226. Bishnoi M, Chopra K, Kulkarni S. Protective effect of curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain. Pharmacol Biochem Behav. 2008;88: 511-22.
227. Xu Y, Ku B, Yao H, Lin Y, Ma X, Zhang Y, Li X. The effects of curcumin on depressive-like behaviors in mice. Eur J Pharmacol. 2005;518:40-6.
228. Ishrat T, Hoda MN, Khan MB, Yousuf S, Ahmad M, Khan MM, Ahmad A, Islam F. Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT). Eur Neuropsychopharmacol. 2009;19:636-47.
229. Ahmed T, Gilani AH. Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease. Pharmacol Biochem Behav. 2009;91:554-9.
230. Ng TP, Chiam PC, Lee T, Chua HC, Lim L, Kua EH. Curry consumption and cognitive function in the elderly. Am J Epidemiol. 2006;164: 898-906.
231. Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol. 2006;545:51-64.
232. Hatcher H, Planalp R, Cho J, Tortia FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 2008; 65:1631-52.
233. Friedman M. Overview of antibacterial, antitoxin, antiviral, and antifungal activities of tea flavonoids and teas. Mol Nutr Food Res. 2007; 51:116-34.
234. Bais HP, Vepachedu R, Gilroy S, Callaway RM, Vivanco JM. Allelopathy and exotic plant invasion: from molecules and genes to species interactions. Science. 2003;301:1377.
235. Kim YS, Lee JH, Kim MN, Kim JO. The effect of hot water-extract and flavor compounds of mugwort on microbial growth. J Korean Soc Food Nutr. 1994;23:994-1000.
236. Song JM, Lee KH, Seong BL. Antiviral effect of catechins in green tea on influenza virus. Antiviral Res. 2005;68:66-74.
237. Mukhtar H, Ahmad N. Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr. 2000;71 (Suppl 6):1698-704.
238. Mandel SA, Amit T, Weinreb O, Reznichenko L, Youdim MBH. Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson Diseases. CNS Neurosci Ther. 2008;14:352-65.
239. Kim SJ, Jeong HJ, Lee KM, Myung NY, An NH, Yang WM, Park SK, Lee HJ, Hong SH, et al. Epigallocatechin-3-gallate suppresses NFkappa B activation and phosphorylation of p38 MAPK and JNK in human astrocytoma U373MG cells. J Nutr Biochem. 2007;18:587-96.
240. Levites Y, Amit T, Mandel S, Youdim MBH. Neuroprotection and neurorescue against A beta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J. 2003;17:952.
241. Bastianetto S, Yao ZX, Papadopoulos V, Quirion R. Neuroprotective effects of green and black teas and their catechin gallate esters against beta-amyloid-induced toxicity. Eur J Neurosci. 2006;23:55-64.
242. Katayama Y, Homma T, Hara Y, Hirai K. Tea catechin, (-)-epigallocatechin gallate, facilitates cholinergic ganglion transmission in the myenteric plexus of the guinea-pig small intestine. Neurosci Lett. 2002; 319:63-6.
243. Reznichenko L, Amit T, Youdim MBH, Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate induces neurorescue of long-term serum-deprived PC12 cells and promotes neurite outgrowth. J Neurochem. 2005;93:1157-67.
244. Rezai-Zadeh K, Arendash GW, Hou H, Fernandez F, Jensen M, Runfeldt M, Shytle RD, Tan J. Green tea epigallocatechin-3-gallate (EGCG) reduces [beta]-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res. 2008;1214:177-87.
245. Koh SH, Lee SM, Kim HY, Lee KY, Lee YJ, Kim HT, Kim J, Kim MH, Hwang MS, et al. The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice. Neurosci Lett. 2006;395: 103-7.
246. Lee YK, Yuk DY, Lee JW, Lee SY, Ha TY, Oh KW, Yun YP, Hong JT. (-)-Epigallocatechin-3-gallate prevents lipopolysaccharide-induced elevation of beta-amyloid generation and memory deficiency. Brain Res. 2009;1250:164-74.
247. Levites Y, Weinreb O, Maor G, Youdim MBH, Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem. 2001;78:1073-82.
248. Lee S, Suh S, Kim S. Protective effects of the green tea polyphenol (-)-epigallocatechin gallate against hippocampal neuronal damage after transient global ischemia in gerbils. Neurosci Lett. 2000;287: 191-4.
249. Park JW, Jang YH, Kim JM, Lee H, Park WK, Lim MB, Chu YK, Lo EH, Lee SR. Green tea polyphenol (-)-epigallocatechin gallate reduces neuronal cell damage and up-regulation of MMP-9 activity in hippocampal CA1 and CA2 areas following transient global cerebral ischemia. J Neurosci Res. 2009;87:567-75.
250. Haque AM, Hashimoto M, Katakura M, Tanabe Y, Hara Y, Shido O. Long-term administration of green tea catechins improves spatial cognition learning ability in rats. International Conference on O-CHA (tea) Culture and Science (ICOS). Shizuoka (Japan): American Society of Nutritional Science; 2004. p. 1043-7.
251. Haque AM, Hashimoto M, Katakura M, Hara Y, Shido O. Green tea catechins prevent cognitive deficits caused by A beta(1-40) in rats. J Nutr Biochem. 2008;19:619-26.
252. Zhang L, Jie G, Zhang J, Zhao B. Significant longevity-extending effects of EGCG on Caenorhabditis elegans under stress. Free Radic Biol Med. 2009;46:414-21.
253. Zheng Y, Layne J, Toborek M, Hennig B. The roles of caveolin-1 and heme oxygenase-1 in EGCG-mediated protection against TNF-{alpha}-induced endothelial inflammation. FASEB J. 2010;24: 541-10.
254. Weinreb O, Mandel S, Amit T, Youdim MBH. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J Nutr Biochem. 2004;15:506-16.
255. Di Carlo G, Borrelli F, Ernst E, Izzo A. St John's wort: Prozac from the plant kingdom. Trends Pharmacol Sci. 2001;22:292-7.
256. Beerhues L. Hyperforin. Phytochemistry. 2006;67:2201-7.
257. Meruelo D, Lavie G, Lavie D. Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin. Proc Natl Acad Sci USA. 1988;85:5230.
258. Zanoli P. Role of hyperforin in the pharmacological activities of St. John's Wort. CNS Drug Rev. 2004;10:203-18.
259. Medina MA, Martínez-Poveda B, Amores-Sánchez MI, Quesada AR. Hyperforin: more than an antidepressant bioactive compound? Life Sci. 2006;79:105-11.
260. Butterweck V, Jurgenliemk G, Nahrstedt A, Winterhoff H. Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test. Planta Med. 2000;66:3-6.
261. Butterweck V, Schmidt M. St. John's wort: role of active compounds for its mechanism of action and efficacy. Wien Med Wochenschr. 2007;157:356-61.
262. Filippini R, Piovan A, Borsarini A, Caniato R. Study of dynamic accumulation of secondary metabolites in three subspecies of Hypericum perforatum. Fitoterapia. 2010;81:115-9.
263. Sirvent T, Gibson D. Induction of hypericins and hyperforin in Hypericum perforatum L. in response to biotic and chemical elicitors* 1. Physiol Mol Plant Pathol. 2002;60:311-20.
264. Xu MJ, Dong JF, Zhu MY. Nitric oxide mediates the fungal elicitorinduced hypericin production of Hypericum perforatum cell suspension cultures through a jasmonic-acid-dependent signal pathway. Plant Physiol. 2005;139:991.
265. Knox J, Dodge A. Isolation and activity of the photodynamic pigment hypericin. Plant Cell Environ. 1985;8:19-25.
266. Butterweck V. Mechanism of action of St John's wort in depression: what is known? CNS Drugs. 2003;17:539-62.
267. Kumar V, Mdzinarishvili A, Kiewert C, Abbruscato T, Bickel U, Schyf C, Klein J. NMDA receptor-antagonistic properties of hyperforin, a constituent of St. John's Wort. J Pharmacol Sci. 2006;102:47-54.
268. Pilkington K, Rampes H, Richardson J. Complementary medicine for depression. Expert Rev Neurother. 2006;6:1741-51.
269. Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev. 2008;CD000448.
270. Chung IM, Park MR, Chun JC, Yun SJ. Resveratrol accumulation and resveratrol synthase gene expression in response to abiotic stresses and hormones in peanut plants. Plant Sci. 2003;164:103-9.
271. Gottstein D, Gross D. Phytoalexins of woody plants. Trees-Structure and Function. 1992;6:55-68.
272. Jung HJ, Hwang IA, Sung WS, Kang H, Kang BS, Seu YB, Lee DG. Fungicidal effect of resveratrol on human infectious fungi. Arch Pharm Res. 2005;28:557-60.
273. Docherty J, Fu M, Stiffler B, Limperos R, Pokabla C, Delucia A. Resveratrol inhibition of herpes simplex virus replication. Antiviral Res. 1999;43:135-45.
274. Faith SA, Sweet TJ, Bailey E, Booth T, Docherty JJ. Resveratrol suppresses nuclear factor-[kappa] B in herpes simplex virus infected cells. Antiviral Res. 2006;72:242-51.
275. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444:337-42.
276. Udenigwe CC, Ramprasath VR, Aluko RE, Jones PJH. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr Rev. 2008;66:445-54.
277. Nijveldt RJ, van Nood E, van Hoorn DEC, Boelens PG, van Norren K, van Leeuwen PAM. Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr. 2001;74:418-25.
278. Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: a molecule whose time has come? And gone? Clin Biochem. 1997;30:91-113.
279. Saiko P, Szakmary A, Jaeger W, Szekeres T. Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res Rev Mutat Res. 2008;658:68-94.
280. Fan E, Zhang LJ, Jiang S, Bai YH. Beneficial effects of resveratrol on atherosclerosis. J Med Food. 2008;11:610-4.
281. Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? Eur J Endocrinol. 1998;138:619-20.
282. Anekonda T. S. Resveratrol-A boon for treating Alzheimer's disease? Brain Research Reviews. 2006;52:316-26.
283. Chen CK, Pace-Asciak CR. Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharmacol. 1996;27:363-6.
284. Gojkovic-Bukarica L, Novakovic A, Kanjuh V, Bumbasirevic M, Lesic A, Heinle H. A role of ion channels in the endothelium-independent relaxation of rat mesenteric artery induced by resveratrol. J Pharmacol Sci. 2008;108:124-30.
285. Novakovic A, Bukarica LG, Kanjuh V, Heinle H. Potassium channelsmediated vasorelaxation of rat aorta induced by resveratrol. Basic Clin Pharmacol Toxicol. 2006b;99:360-4.
286. Novakovic A, Gojkovic-Bukarica L, Peric M, Nezic D, Djukanovic B, Markovic-Lipkovski J, Heinle H. The mechanism of endotheliumindependent relaxation induced by the wine polyphenol resveratrol in human internal mammary artery. J Pharmacol Sci. 2006a;101:85-90.
287. Shen MY, Hsiao G, Liu CL, Fong TH, Lin KH, Chou DS, Sheu JR. Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP. Br J Haematol. 2007;139: 475-85.
288. Jia Z, Zhu H, Misra BR, Mahaney JE, Li YB, Misra HP. EPR studies on the superoxide-scavenging capacity of the nutraceutical resveratrol. Mol Cell Biochem. 2008;313:187-94.
289. Chander V, Chopra K. Protective effect of nitric oxide pathway in resveratrol renal ischemia-reperfusion injury in rats. Arch Med Res. 2006;37:19-26.
290. Li Y, Cao ZX, Zhu H. Upregulation of endogenous antioxidants and phase 2 enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth muscle cells leads to cytoprotection against oxidative and electrophilic stress. Pharmacol Res. 2006;53:6-15.
291. Rubiolo JA, Mithieux G, Vega FV. Resveratrol protects primary rat hepatocytes against oxidative stress damage: Activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. Eur J Pharmacol. 2008;591:66-72.
292. Robb EL, Winkelmolen L, Visanji N, Brotchie J, Stuart JA. Dietary resveratrol administration increases MnSOD expression and activity in mouse brain. Biochem Biophys Res Commun. 2008;372:254-9.
293. Bastianetto S, Brouillette J, Quirion R. Neuroprotective effects of natural products: interaction with intracellular kinases, amyloid peptides and a possible role for transthyretin. Neurochem Res. 2007;32: 1720-5.
294. Marambaud P, Zhao HT, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem. 2005;280: 37377-82.
295. Han YS, Zheng WH, Bastianetto S, Chabot JG, Quirion R. Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br J Pharmacol. 2004;141:997-1005.
296. Karuppagounder SS, Pinto JT, Xu H, Chen H-L, Beal MF, Gibson GE. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int. 2009;54: 111-8.
297. Joseph JA, Fisher DR, Cheng V, Rimando AM, Shukitt-Hale B. Cellular and behavioral effects of stilbene resveratrol analogues: implications for reducing the deleterious effects of aging. J Agric Food Chem. 2008;56:10544-51.
298. Ates O, Cayli S, Altinoz E, Gurses I, Yucel N, Sener M, Kocak A, Yologlu S. Neuroprotection by resveratrol against traumatic brain injury in rats. Antalya (Turkey): 19th Annual Congress of Turkish-Neurosurgery-Society; 2005. p. 137-44.
299. Jin F, Wu Q, Lu YF, Gong QH, Shi JS. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur J Pharmacol. 2008;600:78-82.
300. Sharma M, Gupta YK. Chronic treatment with trans rosveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci. 2002;71:2489-98.
301. Sonmez U, Sonmez A, Erbil G, Tekmen I, Baykara B. Neuroprotective effects of resveratrol against traumatic brain injury in immature rats. Neurosci Lett. 2007;420:133-7.
302. Kumar P, Padi SSV, Naidu PS Kumar A. Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms. Behav Pharmacol. 2006;17: 485-92.
303. Kennedy DO, Wightman EL, Reay JL, Lietz G, Okello E, Wilde AJ, Haskell CF. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr. 2010;91:1590.
304. Murkies AL, Wilcox G, Davis SR. Clinical review 92: phytoestrogens. J Clin Endocrinol Metab. 1998;83:297.
305. Barnes S. The biochemistry, chemistry and physiology of the isoflavones in soybeans and their food products. Lymphat Res Biol. 2010; 8:89-98.
306. Guha N, Kwan ML, Quesenberry CP Jr, Weltzien EK, Castillo AL, Caan BJ. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. Breast Cancer Res Treat. 2009;118:395-405.
307. Sarkaki A, Badavi M, Aligholi H, Moghaddam AZ. Preventive effects of soy meal (+/2 isoflavone) on spatial cognitive deficiency and body weight in an ovariectomized animal model of Parkinson's disease. Pak J Biol Sci. 2009;12:1338-45.
308. Neese SL, Wang VC, Doerge DR, Woodling KA, Andrade JE, Helferich W, Korol D, Schantz SL. Impact of dietary genistein and aging on executive function in rats. Neurotoxicol Teratol. 2010;32:200-11.
309. Lee YB, Lee HJ, Won MH, Hwang IK, Kang TC, Lee JY, Nam SY, Kim KS, Kim E, et al. Soy isoflavones improve spatial delayed matching-toplace performance and reduce cholinergic neuron loss in elderly male rats. J Nutr. 2004;134:1827-31.
310. Bryant M, Cassidy A, Hill C, Powell J, Talbot D, Dye L. Effect of consumption of soy isoflavones on behavioural, somatic and affective symptoms in women with premenstrual syndrome. Br J Nutr. 2005; 93:731-9.
311. Basaria S, Wisniewski A, Dupree K, Bruno T, Song MY, Yao F, Ojumu A, John M, Dobs AS. Effect of high-dose isoflavones on cognition, quality of life, androgens, and lipoprotein in post-menopausal women. J Endocrinol Invest. 2009;32:150-5.
312. Hooper L, Ryder JJ, Kurzer MS, Lampe JW, Messina MJ, Phipps WR, Cassidy A. Effects of soy protein and isoflavones on circulating hormone concentrations in pre-and post-menopausal women: a systematic review and meta-analysis. Hum Reprod Update. 2009;15:423-40.
313. Casini M, Marelli G, Papaleo E, Ferrari A, D'Ambrosio F, Unfer V. Psychological assessment of the effects of treatment with phytoestrogens on postmenopausal women: a randomized, double-blind, crossover, placebo-controlled study. Fertil Steril. 2006;85:972-8.
314. File S, Hartley D, Elsabagh S, Duffy R, Wiseman H. Cognitive improvement after 6 weeks of soy supplements in postmenopausal women is limited to frontal lobe function. Menopause. 2005;12:193.
315. Zhao L, Brinton RD. WHI and WHIMS follow-up and human studies of soy isoflavones on cognition. Expert Rev Neurother. 2007;7:1549-64.
316. Thorp A, Sinn N, Buckley J, Coates A, Howe P. Soya isoflavone supplementation enhances spatial working memory in men. Br J Nutr. 2009;102:1348-54.
317. Pauling L. Evolution and the need for ascorbic acid. Proc Natl Acad Sci USA. 1970;67:1643.
318. Benzie IFF. Evolution of dietary antioxidants. Comp Biochem Physiol A Mol Int Physiol. 2003;136:113-126.
319. Bhat KPL, Kosmeder JW, Pezzuto JM. Biological effects of resveratrol. Antioxid Redox Signal. 2001;3:1041-1064.
320. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5:493-506.
321. Samuelsson G. Drugs of natural origin: a textbook of pharmacognosy. Stockholm: 5th Swedish Pharmaceutical Press; 2004.
322. Humphrey AJ, Beale MH. Terpenes. In: Crozier A, Clifford MH, Ashihara H, editors. Plant secondary metabolites: occurence, structure and role in the human diet. Oxford: Blackwell Publishing; 2006.
323. Singh M, Arseneault M, Sanderson T, Murthy V, Ramassamy C. Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. J Agric Food Chem. 2008;56:4855-73.
324. Williamson EM. Synergy and other interactions in phytomedicines. Phytomedicine. 2001;8:401-9.
325. Spinella M. The importance of pharmacological synergy in psychoactive herbal medicines. Altern Med Rev. 2002;7:130-7.